TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9003138

Group type: EXPERIMENTAL
Intervention: Telephone support (intervention calls at 3, 9, and 21 months after cessation clinic quit date)
Number of subjects: 1083

Group type: COMPARATOR
Intervention: No further intervention (control group)
Number of subjects: 1083
Study: 1298545

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg once a day (n=13)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg once a day + Gemfibrozil 600 mg daily (n=11)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Diet only (Control group, n=14)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg once a day
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg once a day + Gemfibrozil 600 mg daily
Number of subjects: 38
Study: 6209346

Group type: EXPERIMENTAL
Intervention: Presurgical treatment with 3.5 X 10(4) units of leukocyte interferon/kg (3 injections)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Postsurgical treatment with placebo (7 injections)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo (10 injections)
Number of subjects: 55
Study: 31257591

Group type: EXPERIMENTAL
Intervention: AMX + MET (500 mg three times a day and 400 mg three times a day for 7 days)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: CLM (500 mg twice a day for 7 days)
Number of subjects: 46

Group type: COMPARATOR
Intervention: CLM
Number of subjects: 46
Study: 29969614

Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle intervention (cognitive training, nutrition counseling, and advice on physical activity)
Number of subjects: 1637

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 1637
Study: 26802176

Group type: COMPARATOR
Intervention: MPT-T (melphalan, prednisone, thalidomide)
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: MPR-R (melphalan, prednisone, lenalidomide)
Number of subjects: 668

Group type: COMPARATOR
Intervention: MPT-T
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: MPR-R
Number of subjects: 668
Study: 24491005

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (Zg) for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (Pg) for 6 months
Number of subjects: 60
Study: 22640773

Group type: EXPERIMENTAL
Intervention: Kana Pick‐out Test (KPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single task components (reading or vowel pick‐out alone)
Number of subjects: 0
Study: 20298652

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA) pulpotomy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Eugenol-free FS pulpotomy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Ferric sulfate (FS) pulpotomy
Number of subjects: 92

Group type: COMPARATOR
Intervention: FS/MTA pulpotomy
Number of subjects: 92
Study: 18357902

Group type: EXPERIMENTAL
Intervention: Rehabilitation with prosthetics
Number of subjects: 40

Group type: COMPARATOR
Intervention: Amputated limb
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-amputated limb
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hip flexors
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hip extensors
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hip abductors
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hip adductors
Number of subjects: 40
Study: 15680926

Group type: EXPERIMENTAL
Intervention: Internet-delivered behavioral regimen (progressive relaxation, limited biofeedback with autogenic training, and stress management)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Internet-delivered behavioral regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Symptom monitoring waitlist control
Number of subjects: 0
Study: 12042231

Group type: EXPERIMENTAL
Intervention: Brief cognitive-behavioural therapy (CBT), n=257
Number of subjects: 422

Group type: COMPARATOR
Intervention: Treatment as usual (control group), n=165
Number of subjects: 422
Study: 10192710

Group type: EXPERIMENTAL
Intervention: BCG vaccine given simultaneously with DTaP vaccine
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: 2-4-6-month spaced schedule
Number of subjects: 390

Group type: COMPARATOR
Intervention: 2-3-4-month accelerated schedule
Number of subjects: 390
Study: 7762855

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg diltiazem
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg diltiazem
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 1 mg/kg lidocaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: saline
Number of subjects: 80
Study: 1702899

Group type: EXPERIMENTAL
Intervention: Isoprinosine 3 g/day for 28 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isoprinosine
Number of subjects: 8
Study: 6775742

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of papaveretum (1 mg/min loading dose, followed by 8 times the loading dose over 48 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent intramuscular dose of papaveretum (0.25 mg/kg at four hourly intervals as necessary)
Number of subjects: 0
Study: 31886526

Group type: EXPERIMENTAL
Intervention: Multicomponent programs incorporating exercise and nutrition-based strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmaceutical and other innovative therapeutic strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 31020742

Group type: EXPERIMENTAL
Intervention: Tailored education (six 45-60 min individual education and follow-up telephone counselling sessions)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard of care only
Number of subjects: 69
Study: 28211797

Group type: EXPERIMENTAL
Intervention: TTM intervention
Number of subjects: 126
Study: 25596266

Group type: EXPERIMENTAL
Intervention: rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone
Number of subjects: 428

Group type: COMPARATOR
Intervention: rituximab-cyclophosphamide-vincristine-prednisone
Number of subjects: 428

Group type: COMPARATOR
Intervention: rituximab-fludarabine-mitoxantrone
Number of subjects: 428
Study: 24135720

Group type: EXPERIMENTAL
Intervention: 16 weeks of continuously supervised moderate-to-high intensity aerobic exercise
Number of subjects: 192

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 192
Study: 21666937

Group type: EXPERIMENTAL
Intervention: Stepwise stent deployment (SSD)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Conventional stent deployment (CSD)
Number of subjects: 403
Study: 19425875

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring with real-time access (RTA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Continuous glucose monitoring with retrospective analysis (RA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Baseline satisfaction with CGM
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Depression scores
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diabetes-related distress
Number of subjects: 50

Group type: COMPARATOR
Intervention: State anxiety
Number of subjects: 50
Study: 16961448

Group type: EXPERIMENTAL
Intervention: 3-S therapy (8 weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 72
Study: 15580055

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10697060

Group type: EXPERIMENTAL
Intervention: Estrogen 0.625 mg/d
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Estrogen 1.25 mg/d
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined estrogen groups
Number of subjects: 120
Study: 9328698

Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 37598

Group type: COMPARATOR
Intervention: Thrombolytic therapy
Number of subjects: 37598
Study: 8223057

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 86

Group type: COMPARATOR
Intervention: Scalpel excision
Number of subjects: 86
Study: 3544189

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg at night)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Low-dose antacid (400 mg of aluminum hydroxide plus 400 mg of magnesium hydroxide four times a day)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combination therapy (cimetidine and low-dose antacid)
Number of subjects: 75
Study: 30388194

Group type: EXPERIMENTAL
Intervention: Tafenoquine (n = 12), single 200-mg dose on days 1, 2, 3, and 10
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (n = 4)
Number of subjects: 16
Study: 29565608

Group type: EXPERIMENTAL
Intervention: Listening Passage Preview (LPP) + Repeated Readings (RR)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Repeated Readings (RR)
Number of subjects: 57
Study: 26741823

Group type: EXPERIMENTAL
Intervention: High-fiber white rice (HFWR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Commercial white rice (WR)
Number of subjects: 30
Study: 25066555

Group type: EXPERIMENTAL
Intervention: Implantable monitoring device (IMD) with alerting feature turned on
Number of subjects: 0

Group type: COMPARATOR
Intervention: Implantable monitoring device (IMD) with alerting feature turned off
Number of subjects: 0
Study: 22914392

Group type: EXPERIMENTAL
Intervention: Progesterone treatment (n=258)
Number of subjects: 523

Group type: COMPARATOR
Intervention: Placebo treatment (n=265)
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: IL-8 levels at 18-24 weeks of gestation
Number of subjects: 523
Study: 19892086

Group type: EXPERIMENTAL
Intervention: Manualized and workbook-driven individual cognitive-behavioral treatment for social anxiety disorder
Number of subjects: 38

Group type: COMPARATOR
Intervention: Delayed treatment for 20 weeks
Number of subjects: 38
Study: 17684877

Group type: EXPERIMENTAL
Intervention: 5 mg hyperbaric bupivacaine 0.5% + 25 microg fentanyl
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 7.5 mg hyperbaric bupivacaine 0.5% + 25 microg fentanyl
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10 mg hyperbaric bupivacaine 0.5% + 25 microg fentanyl
Number of subjects: 60
Study: 15862475

Group type: EXPERIMENTAL
Intervention: Induced catastrophizing about pain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no induced catastrophizing)
Number of subjects: 0
Study: 12532901

Group type: EXPERIMENTAL
Intervention: Glutamine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 9650877

Group type: EXPERIMENTAL
Intervention: Herbal extract mouthwash (6.3 mg/ml)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Minus active control mouthrinse
Number of subjects: 45
Study: 8583518

Group type: EXPERIMENTAL
Intervention: Recovery Attitude and Treatment Evaluator (RAATE) completed by patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recovery Attitude and Treatment Evaluator (RAATE) completed by clinicians
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Less than 1 month of treatment
Number of subjects: 0
Study: 2678688

Group type: EXPERIMENTAL
Intervention: High-dose interferon (100 x 10(6) IU)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Low-dose interferon (10 x 10(6) IU)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intravesical interferon
Number of subjects: 19
Study: 782141

Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 31162569

Group type: EXPERIMENTAL
Intervention: Home-based strength and balance retraining exercise program delivered by a physical therapist (n=173)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Usual care provided by a geriatrician (n=172)
Number of subjects: 345
Study: 28349667

Group type: COMPARATOR
Intervention: High-glycemic-index diet (HiGIX; 80 +/- 0.6 units) combined with supervised exercise (1 h/d, 5 d/wk at 85% HRmax) for 12 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Low-glycemic-index diet (LoGIX; 40 +/- 0.3 units) combined with supervised exercise (1 h/d, 5 d/wk at 85% HRmax) for 12 weeks
Number of subjects: 19
Study: 24451365

Group type: EXPERIMENTAL
Intervention: Enhanced balance and postural control exercises (EB)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard balance exercises (SB)
Number of subjects: 23
Study: 24050377

Group type: EXPERIMENTAL
Intervention: BP card with added semi-structured nurse counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: BP card only (not explicitly mentioned but implied as part of usual care)
Number of subjects: 0
Study: 21975132

Group type: EXPERIMENTAL
Intervention: REFLEX intervention (12 sessions group training)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control condition (cognitive remediation exercises in a group)
Number of subjects: 0
Study: 17910386

Group type: EXPERIMENTAL
Intervention: 4 h/night sleep
Number of subjects: 18

Group type: COMPARATOR
Intervention: 8 h/night sleep
Number of subjects: 18
Study: 16254264

Group type: EXPERIMENTAL
Intervention: Sodium-citrate plasma
Number of subjects: 80

Group type: COMPARATOR
Intervention: Serum
Number of subjects: 80
Study: 12440605

Group type: EXPERIMENTAL
Intervention: Port access CABG (group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional CABG (group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 10208143

Group type: EXPERIMENTAL
Intervention: Oxandrolone, 20 mg/d
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7885427

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches (15 mg for 16 hours daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches
Number of subjects: 80
Study: 2515940

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Gestodene (GES)
Number of subjects: 33
Study: 356980

Group type: EXPERIMENTAL
Intervention: Intermittent bolus DTIC and actinomycin D (starting at 650 mg/m2 and 1 mg/m2 respectively, courses repeated at 3-4 week intervals)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intermittent bolus DTIC and actinomycin D
Number of subjects: 26
Study: 30538068

Group type: COMPARATOR
Intervention: Systemic therapy-naive patients with BM
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Matched patients without BM
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Patients with BM in favorable-risk group
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Patients with BM in intermediate-risk group
Number of subjects: 268

Group type: COMPARATOR
Intervention: Patients without BM in intermediate-risk group
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Patients with BM in poor-risk group
Number of subjects: 268

Group type: COMPARATOR
Intervention: Patients without BM in poor-risk group
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Patients developing BM while on first-line systemic therapy
Number of subjects: 268

Group type: COMPARATOR
Intervention: Patients without BM while on first-line systemic therapy
Number of subjects: 268
Study: 27756786

Group type: EXPERIMENTAL
Intervention: Degarelix only
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Degarelix/bicalutamide
Number of subjects: 39

Group type: COMPARATOR
Intervention: LHRH agonist/bicalutamide
Number of subjects: 39
Study: 29392002

Group type: EXPERIMENTAL
Intervention: Adenoid vegetation with Dermatophagoides Pteronyssinus and/or D. farinae allergy (Group II)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Adenoid vegetation only (Group I)
Number of subjects: 84
Study: 24119182

Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5/25 mg daily
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Metoprolol 50/100 mg daily
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nebivolol 2.5/5 mg daily
Number of subjects: 75
Study: 21428248

Group type: EXPERIMENTAL
Intervention: Thymol + eugenol vaginal douche (SD) 1 douche/day for 1 week
Number of subjects: 459

Group type: COMPARATOR
Intervention: Metronidazole vaginal suppository 1/night for 1 week
Number of subjects: 459

Group type: COMPARATOR
Intervention: Econazole vaginal suppository 1/night for 3 days
Number of subjects: 459
Study: 19427775

Group type: EXPERIMENTAL
Intervention: Crocus sativus (saffron) 200mg tablet taken daily for ten days
Number of subjects: 20
Study: 16997936

Group type: EXPERIMENTAL
Intervention: DHEA treatment (75 mg daily for an average of 17.6 weeks)
Number of subjects: 25
Study: 14691415

Group type: EXPERIMENTAL
Intervention: Vascular closure devices (CDs)
Number of subjects: 4736

Group type: COMPARATOR
Intervention: Manual compression (MC)
Number of subjects: 4736
Study: 12003058

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 459

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 459
Study: 9785763

Group type: EXPERIMENTAL
Intervention: IMZ SPECT with 123I‐IMZ (167 or 222 MBq)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: IMZ SPECT
Number of subjects: 17
Study: 7697142

Group type: EXPERIMENTAL
Intervention: Red cedar dust delivered through a rotahaler
Number of subjects: 9

Group type: COMPARATOR
Intervention: Spruce dust (control)
Number of subjects: 9
Study: 2487936

Group type: EXPERIMENTAL
Intervention: Warmed 0.5% bupivacaine at 37 degrees C
Number of subjects: 40

Group type: COMPARATOR
Intervention: Glucose-free 0.5% bupivacaine at room temperature (approximately 20 degrees C)
Number of subjects: 40
Study: 363252

Group type: EXPERIMENTAL
Intervention: Methotrexate alone
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Methotrexate plus mercaptopurine
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Methotrexate plus mercaptopurine plus cyclophosphamide
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Methotrexate plus mercaptopurine plus cyclophosphamide plus arabinosyl cytosine
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Additional early therapy
Number of subjects: 282
Study: 30861594

Group type: EXPERIMENTAL
Intervention: Provision of free diabetes supplies
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Proactive telephonic advice by a diabetes educator
Number of subjects: 85

Group type: COMPARATOR
Intervention: Usual care (non-telephone group)
Number of subjects: 85
Study: 28324754

Group type: EXPERIMENTAL
Intervention: TENS group (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham group (n=20)
Number of subjects: 40
Study: 25472980

Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 331
Study: 22841131

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 29
Study: 21860053

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Cognitive Remediation (CR)
Number of subjects: 198
Study: 19420003

Group type: EXPERIMENTAL
Intervention: Single intracoronary infusion of bone marrow mononuclear cells (BMC) (1.9 +/- 1.2 x 10^8) at 3-7 days after AMI
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: BMC administration both at 3-7 days (2.0 +/- 1.4 x 10^8) and at 3 months (2.1 +/- 1.7 x 10^8)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo injection at 3-7 days
Number of subjects: 39
Study: 17605559

Group type: EXPERIMENTAL
Intervention: Telephone-based individualized feedback
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Print-based individualized feedback
Number of subjects: 239

Group type: COMPARATOR
Intervention: Contact control
Number of subjects: 239
Study: 14736927

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy (at least 240 mg/m²); 932 patients assigned to chemotherapy
Number of subjects: 1867

Group type: COMPARATOR
Intervention: Observation; 935 patients assigned to observation
Number of subjects: 1867
Study: 11561496

Group type: EXPERIMENTAL
Intervention: Lateral position
Number of subjects: 74

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 74
Study: 9784911

Group type: EXPERIMENTAL
Intervention: Dipyridamole (300 mg/d) for 6 months
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dilazep (300 mg/d) for 6 months
Number of subjects: 22
Study: 7870560

Group type: EXPERIMENTAL
Intervention: Depressed mood group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nondepressed group
Number of subjects: 40
Study: 2832764

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with thoracic irradiation (protocol 78 LUN 328)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with simultaneous radiotherapy (protocol LUN 81343)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Combination chemotherapy alone (control group)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Local control at 12 months (both protocols)
Number of subjects: 660
Study: 30514660

Group type: EXPERIMENTAL
Intervention: CFS label
Number of subjects: 207

Group type: COMPARATOR
Intervention: No label
Number of subjects: 207
Study: 29470530

Group type: EXPERIMENTAL
Intervention: Health education intervention regarding tuberculosis using the developed module
Number of subjects: 226

Group type: COMPARATOR
Intervention: Normal services provided for HIV patients
Number of subjects: 226
Study: 27694262

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 24861826

Group type: EXPERIMENTAL
Intervention: 5° lateral wedge insoles
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (standard shoe)
Number of subjects: 8
Study: 22332908

Group type: EXPERIMENTAL
Intervention: 5 mg trans-resveratrol twice daily for 12 weeks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 50 mg trans-resveratrol twice daily for 12 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 20163869

Group type: EXPERIMENTAL
Intervention: Bangerter filters
Number of subjects: 186

Group type: COMPARATOR
Intervention: Patching
Number of subjects: 186
Study: 17581311

Group type: EXPERIMENTAL
Intervention: Calorie-restricted diet
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Calorie-restricted diet plus aerobic exercise
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (diet only)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (diet plus exercise)
Number of subjects: 42
Study: 15800296

Group type: EXPERIMENTAL
Intervention: Obese patients
Number of subjects: 509